Altimmune Inc. Common Stock (NASDAQ:ALT)

Real-time price: | Most recent change:0.00%

Altimmune, Inc. is a clinical-stage immunotherapeutics company. It focused on the development of products to stimulate robust and durable immune responses for the prevention and treatment of disease. The company's proprietary platform technologies consist of RespirVec and Densigen. Altimmune Inc., formerly known as Pharmathene Inc., is based in Gaithersburg, United States....

+See More


Here we provide our AYA proprietary alpha stock signals for all premium members on our AYA fintech network platform. Specifically, a high Fama-French multi-factor dynamic conditional alpha suggests that the stock is likely to consistently outperform the broader stock market benchmarks such as S&P 500, Dow Jones, Nasdaq, Russell 3000, MSCI USA, and MSCI World etc. Since March 2023, our proprietary alpha stock signals retain U.S. Patent and Trademark Office (USPTO) fintech patent protection, approval, and accreditation for 20 years. Our homepage and blog articles provide more details on this proprietary alpha stock market investment model with robust long-term historical backtest evidence.

Sharpe-Lintner-Black CAPM alpha (Premium Members Only) Fama-French (1993) 3-factor alpha (Premium Members Only) Fama-French-Carhart 4-factor alpha (Premium Members Only) Fama-French (2015) 5-factor alpha (Premium Members Only) Fama-French-Carhart 6-factor alpha (Premium Members Only) Dynamic conditional 6-factor alpha (Premium Members Only) Last update: Saturday 3 May 2025

Blog+More

AT&T wins court approval to take over Time Warner with a trademark $85 billion bid despite the Trump prior dissent due to antitrust concerns.

Chanel Holden

2018-06-07 10:36:00 Thursday ET

AT&T wins court approval to take over Time Warner with a trademark $85 billion bid despite the Trump prior dissent due to antitrust concerns.

AT&T wins court approval to take over Time Warner with a trademark $85 billion bid despite the Trump administration prior dissent due to antitrust conce

+See More

American China-specialists champion the key notion of *strategic engagement* with the Xi administration.

James Campbell

2018-12-11 10:34:06 Tuesday ET

American China-specialists champion the key notion of *strategic engagement* with the Xi administration.

Several eminent American China-specialists champion the key notion of *strategic engagement* with the Xi administration. From the Hoover Institution at Stan

+See More

From crony capitalism to state capitalism, what economic policy lessons can we learn from Putin's reign in Russia?

Jonah Whanau

2018-03-13 07:34:00 Tuesday ET

From crony capitalism to state capitalism, what economic policy lessons can we learn from Putin's reign in Russia?

From crony capitalism to state capitalism, what economic policy lessons can we learn from President Putin's current reign in Russia? In the 15 years of

+See More

Former White House chief economic advisor Gary Cohn points out that there is no instant cure for the Sino-U.S. trade dilemma.

Rose Prince

2018-11-23 09:39:00 Friday ET

Former White House chief economic advisor Gary Cohn points out that there is no instant cure for the Sino-U.S. trade dilemma.

Former White House chief economic advisor Gary Cohn points out that there is no instant cure for the Sino-U.S. trade dilemma. After the U.S. midterm electio

+See More

St Louis Federal Reserve President James Bullard indicates that his ideal baseline scenario remains a mutually beneficial China-U.S. trade deal.

Charlene Vos

2019-06-09 11:29:00 Sunday ET

St Louis Federal Reserve President James Bullard indicates that his ideal baseline scenario remains a mutually beneficial China-U.S. trade deal.

St Louis Federal Reserve President James Bullard indicates that his ideal baseline scenario remains a mutually beneficial China-U.S. trade deal. Bullard ind

+See More

Former LSE Director Howard Davies shares his ingenious insights into the new Basel 4 accord.

Chanel Holden

2018-01-01 06:30:00 Monday ET

Former LSE Director Howard Davies shares his ingenious insights into the new Basel 4 accord.

As former chairman of the British Financial Services Authority and former director of the London School of Economics, Howard Davies shares his ingenious ins

+See More